Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock
Source: View publication →
In patients with early septic shock, a resuscitation strategy targeting the normalization of capillary refill time did not significantly reduce 28-day all-cause mortality compared to a strategy targeting serum lactate levels.
Key Findings
Study Design
Study Limitations
Clinical Significance
While the trial did not reach statistical significance for its primary mortality endpoint, the results suggest that capillary refill time is a safe, resource-independent alternative to lactate-guided resuscitation that may result in less organ dysfunction and potentially lower fluid requirements during early septic shock management.
Historical Context
For years, the Surviving Sepsis Campaign guidelines recommended normalizing serum lactate levels as a marker of tissue hypoperfusion. However, limitations regarding the specificity of lactate—which can be elevated due to non-hypoxic causes—and the time required for lab results prompted interest in alternative, rapid clinical markers of peripheral perfusion.
Guided Discussion
High-yield insights from every perspective
What is the physiological basis for using capillary refill time (CRT) as a bedside indicator of shock, and how does it fundamentally differ from serum lactate as a marker of tissue perfusion?
Key Response
CRT measures peripheral vasomotor tone and capillary flow; it is an instantaneous physical sign of skin perfusion. In contrast, serum lactate is a delayed metabolic byproduct of anaerobic metabolism or stress-induced glycolysis. Understanding this distinction is key to clinical reasoning, as lactate can remain elevated ('lactate lag') even after perfusion has been restored, whereas CRT provides real-time feedback on the microcirculatory response to resuscitation.
In a patient with early septic shock who has achieved a Mean Arterial Pressure (MAP) of 65 mmHg but still has a CRT >3 seconds, what is the next step in the ANDROMEDA-SHOCK protocol, and why might this approach be preferable to chasing a lactate clearance of 10%?
Key Response
The protocol suggests a sequential approach: fluid challenges, followed by vasopressor titration, and then potentially an inodilator or 'minibolus' if perfusion remains poor. CRT-guided therapy may be preferable because it prevents the 'over-resuscitation' often seen when clinicians continue fluid boluses for a persistently high lactate that may be caused by impaired hepatic clearance or adrenergic stimulation rather than ongoing hypovolemia.
How does the ANDROMEDA-SHOCK trial challenge the 'Macro-Microcirculation dissociation' theory, and what are the implications for using CRT as a surrogate for splanchnic or renal perfusion in the ICU?
Key Response
The trial demonstrates that peripheral perfusion (skin) can serve as a proxy for the 'adequacy' of the resuscitation. If peripheral perfusion normalizes, it suggests that the compensatory sympathetic vasoconstriction has eased, which generally correlates with improved perfusion to more vital beds. For a fellow, this underscores the importance of 'hemodynamic coherence'—the idea that our macro-hemodynamic targets (MAP) should lead to improved micro-hemodynamic flow.
The primary endpoint of 28-day mortality showed a p-value of 0.06 in favor of CRT-guided therapy. How should this 'near-significant' result influence your bedside teaching and your willingness to adopt CRT as a primary resuscitation target over traditional lactate-guided goals?
Key Response
An attending should recognize that the study was likely underpowered for its ambitious 15% mortality reduction goal. Given that CRT is free, non-invasive, and showed a 20% relative risk reduction and less organ dysfunction (SOFA score at 72 hours), it represents a high-value, low-risk shift in practice. Teaching should emphasize that a 'negative' p-value does not equate to 'no effect,' especially when the point estimate and secondary outcomes strongly favor the intervention.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ANDROMEDA-SHOCK trial calculated its sample size based on a projected 15% absolute risk reduction in mortality. Critically evaluate the impact of this power calculation on the study's Frequentist interpretation and discuss how a Bayesian re-analysis might alter the perceived utility of CRT.
Key Response
A 15% ARR is exceptionally high for a single critical care intervention, leading to an underpowered study for more realistic effect sizes. A PhD candidate should note that Bayesian post-hoc analyses of ANDROMEDA-SHOCK data have shown a >90% posterior probability that CRT-guided therapy is superior to lactate-guided therapy, highlighting the limitations of binary p-value thresholds in clinical trials with high-stakes outcomes like mortality.
As a reviewer, what concerns would you raise regarding the 'open-label' nature of the CRT assessment versus the objective nature of laboratory-measured lactate, and how might this 'ascertainment bias' affect the internal validity of the protocol adherence?
Key Response
While mortality is an objective outcome, the 'next steps' in the resuscitation protocol (fluids, vasopressors) were triggered by the clinician's assessment of CRT. Since CRT is somewhat subjective (despite the glass-slide standardization), there is a risk that clinicians biased by the study's hypothesis might subconsciously or consciously accelerate or withhold fluids differently than they would in the lactate arm, potentially confounding the results.
The 2021 Surviving Sepsis Campaign guidelines issued a 'weak recommendation' (Low quality of evidence) for using CRT to guide resuscitation. Based on the ANDROMEDA-SHOCK findings, should CRT be elevated to a 'strong' recommendation, and how does it compare to the current 1B evidence for lactate monitoring?
Key Response
Guideline committees look for reproducibility. While ANDROMEDA-SHOCK provides strong evidence for CRT's safety and possible superiority in reducing fluid overload, the 'weak' recommendation often remains until a second large RCT (like the ongoing ANDROMEDA-SHOCK-2) confirms the findings. Currently, lactate remains the standard because of decades of data, but CRT is now formally recognized as an 'adjunct' that provides a faster, cost-effective feedback loop in the first 6-8 hours of shock.
Clinical Landscape
Noteworthy Related Trials
Rivers Early Goal-Directed Therapy Trial
Tested
Early goal-directed therapy (EGDT) targeting central venous oxygen saturation
Population
Patients presenting to the ED with severe sepsis or septic shock
Comparator
Standard care
Endpoint
60-day in-hospital mortality
ProCESS Trial
Tested
Protocol-based EGDT versus protocol-based standard care versus usual care
Population
Patients with septic shock in the emergency department
Comparator
Standard care and usual care
Endpoint
60-day in-hospital mortality
ARISE Trial
Tested
Early goal-directed therapy (EGDT) versus standard care
Population
Patients with early septic shock presenting to the emergency department
Comparator
Standard care
Endpoint
90-day all-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis